Biomarkers in psychotropic drug development

被引：5

作者：

Ahmed, S ^{[1
]}

Mozley, PD ^{[1
]}

Potter, WZ ^{[1
]}

机构：

[1] Lilly Res Labs, Indianapolis, IN USA

来源：

AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY | 2002年 / 10卷 / 06期

关键词：

D O I：

10.1176/appi.ajgp.10.6.678

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 ; 0303 ; 100203 ;

摘要：

The authors review the use of biomarkers in the development of novel psychotropic agents. They briefly review clinical drug development, emphasizing the importance of incorporating biomarkers. For the development of psychotropic agents, biomarkers are particularly useful for assessing central nervous system exposure and effects and for serving as surrogate measures for safety and efficacy. Collectively, biomarkers allow for more accurate estimation of doses for clinical trials as drug development progresses, For drugs that target the pathophysiology of Alzheimer disease, several promising biomarkers are becoming available that may allow improved signal detection in clinical trials. Procedures for developing new drugs are evolving rapidly. Technical advances in the field are making it possible to shift from empirically-based methods to mechanistically-driven schemes, Biomarkers enhance the quality and safety of clinical drug development and reduce its cost and duration.

引用

收藏

页码：678 / 686

页数：9

相关论文

共 113 条

[1] Effect of the 5-HT1A partial agonist buspirone on regional brain electrical activity in man:: a functional neuroimaging study using low-resolution electromagnetic tomography (LORETA) [J].

Anderer, P ;

Saletu, B ;

Pascual-Marqui, RD .

PSYCHIATRY RESEARCH-NEUROIMAGING, 2000, 100 (02) :81-96

[2] Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample [J].

Andreasen, N ;

Minthon, L ;

Clarberg, A ;

Davidsson, P ;

Gottfries, J ;

Vanmechelen, E ;

Vanderstichele, H ;

Winblad, B ;

Blennow, K .

NEUROLOGY, 1999, 53 (07) :1488-1494

[3] Cerebrospinal fluid β-amyloid(1-42) in Alzheimer disease -: Differences between early- and late-onset Alzheimer disease and stability during the course of disease [J].

Andreasen, N ;

Hesse, C ;

Davidsson, P ;

Minthon, L ;

Wallin, A ;

Winblad, B ;

Vanderstichele, H ;

Vanmechelen, E ;

Blennow, K .

ARCHIVES OF NEUROLOGY, 1999, 56 (06) :673-680

[4]

ASBERG M, 1973, CLIN PHARMACOL THER, V14, P277

[5] DOSE-DEPENDENT OCCUPANCY OF CENTRAL DOPAMINE-D(2) RECEPTORS BY THE NOVEL NEUROLEPTIC CP-88,059-01 - A STUDY USING POSITRON EMISSION TOMOGRAPHY AND C-11 RACLOPRIDE [J].

BENCH, CJ ;

LAMMERTSMA, AA ;

DOLAN, RJ ;

GRASBY, PM ;

WARRINGTON, SJ ;

GUNN, K ;

CUDDIGAN, M ;

TURTON, DJ ;

OSMAN, S ;

FRACKOWIAK, RSJ .

PSYCHOPHARMACOLOGY, 1993, 112 (2-3) :308-314

[6] Deposition and disposition of [11C]zanamivir following administration as an intranasal spray -: Evaluation with positron emission tomography [J].

Bergstrom, M ;

Cass, LMR ;

Valind, S ;

Westerberg, G ;

Lundberg, EL ;

Gray, S ;

Bye, A ;

Langstrom, B .

CLINICAL PHARMACOKINETICS, 1999, 36 (Suppl 1) :33-39

[7] The use of pindolol with fluoxetine in the treatment of major depression: Final results from a double-blind, placebo-controlled trial [J].

Berman, RM ;

Anand, A ;

Cappiello, A ;

Miller, HL ;

Hu, XS ;

Oren, DA ;

Charney, DS .

BIOLOGICAL PSYCHIATRY, 1999, 45 (09) :1170-1177

[8]

Bloom AS, 1999, HUM BRAIN MAPP, V8, P235, DOI 10.1002/(SICI)1097-0193(1999)8:4<235::AID-HBM7>3.0.CO

[9]

2-3

[10] Patterns of brain activation in people at risk for Alzheimer's disease [J].

Bookheimer, SY ;

Strojwas, MH ;

Cohen, MS ;

Saunders, AM ;

Pericak-Vance, MA ;

Mazziotta, JC ;

Small, GW .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (07) :450-456

← 1 2 3 4 5 6 7 8 9 10 →